Velorum Therapeutics
Innovative heme‑focused biologics for rare porphyrias and heme‑driven diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Innovative heme‑focused biologics for rare porphyrias and heme‑driven diseases.
OncologyHematologyKidney disease
Technology Platform
Engineered protein biologics that scavenge toxic porphyrins or sequester free heme, providing disease‑modifying activity across porphyrias, cancer, and organ injury.
Opportunities
Unmet need in rare porphyrias and a large oncology market where heme metabolism is a driver; platform can be extended to multiple heme‑related diseases.
Risk Factors
Scientific validation of heme‑targeting biologics, regulatory path for novel mechanism, and competition from other metabolic oncology approaches.
Competitive Landscape
Few companies target heme directly; Velorum differentiates through proprietary porphyrin‑scavenging and heme‑sequestering proteins that address both rare and high‑volume indications.